Brokers Issue Forecasts for TARS FY2025 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Analysts at Lifesci Capital issued their FY2025 EPS estimates for Tarsus Pharmaceuticals in a note issued to investors on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville anticipates that the company will post earnings of ($1.65) per share for the year. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q4 2025 earnings at ($0.11) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million during the quarter, compared to analysts’ expectations of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.

A number of other equities analysts have also issued reports on the stock. Guggenheim reissued a “buy” rating and set a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday. Barclays lowered their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday. The Goldman Sachs Group increased their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Finally, Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $61.33.

Tarsus Pharmaceuticals Trading Up 2.3 %

Tarsus Pharmaceuticals stock opened at $43.55 on Thursday. The stock has a 50-day moving average price of $51.14 and a 200 day moving average price of $43.00. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of -11.43 and a beta of 1.01. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its position in Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after purchasing an additional 420,057 shares in the last quarter. Creative Planning acquired a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter worth approximately $362,000. Vestal Point Capital LP purchased a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at approximately $7,565,000. Jennison Associates LLC grew its stake in Tarsus Pharmaceuticals by 14.8% in the 4th quarter. Jennison Associates LLC now owns 2,500,132 shares of the company’s stock valued at $138,432,000 after acquiring an additional 321,552 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in Tarsus Pharmaceuticals in the 3rd quarter worth $763,000. 90.01% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.